@article{d44baec18d1c452e9973fb7f1b08d886,
title = "Guidance for contemporary use of biologics in management of chronic rhinosinusitis with nasal polyps: discussion from a National Institutes of Health–sponsored workshop",
abstract = "Background: Biologic medications are emerging as options for treating chronic rhinosinusitis with nasal polyps (CRSwNP). Several questions remain regarding patient selection, indications, clinical efficacy, and cost effectiveness. Methods: In November 2019, a group of physicians and scientists gathered to consider strategies for future studies regarding biologics. During the discussion, gaps in knowledge highlighted a need for a consensus on the present day use of biologics in polyp patients. Results: The goal of this guideline is to propose recommendations for the current use of biologics in CRSwNP as new evidence continues to emerge and inform practice. Conclusion: We suggest that physicians evaluate patients on an individual basis and closely monitor for improvement due to the high cost and unknown long-term effects of biologics.",
keywords = "chronic rhinosinusitis, endoscopic sinus surgery, guideline, medical therapy of chronic rhinosinusitis, topical therapy for chronic rhinosinusitis",
author = "Roland, {Lauren T.} and Smith, {Timothy L.} and Schlosser, {Rodney J.} and Soler, {Zachary M.} and Peters, {Anju T.} and Laidlaw, {Tanya M.} and Bleier, {Benjamin S.} and Vijay Ramakrishnan and Elina Toskala and Kennedy, {David W.} and Luong, {Amber U.}",
note = "Funding Information: Potential conflicts of interest: L.T.R.: Consultant for Tissium. T.L.S.: Research support from the NIH. R.J.S.: Consulting and/or speaker arrangements with Stryker, Olympus, Optinose, GSK, Regeneron, and Roche; owns stock/equity in Healthy Humming; receives research support from Gossamer, Stryker, Optinose, GSK, AstraZeneca, Regeneron, Roche, and Healthy Humming. Z.M.S.: Consultant for Olympus, Optinose, Novartis, Regeneron and Healthy Humming. A.T.P.: Consultant for Astra Zeneca, Sanofi Regeneron, and Optinose. T.M.L.: Consultant for GSK and Regeneron. B.S.B.: funding from the NIH/National Institute of Neurological Disorders and Stroke (NINDS) (R01 NS108968‐01); Consultant for Olympus, Karl Storz, Medtronic, Sinopsys, Baxter, and 3D Matrix; Equity in Interscope; Royalties from Thieme. V.R.: Consultant for Medtronic, Inc. and Optinose US, which are not affiliated with this investigation. V.R.R.: Supported by NIH/National Institute on Deafness and Other Communication Disorders (NIDCD) (K23 DC014747). E.T.: Consultant for Fiagan; Advisory board of Optinose; has received research support from Sanofi. D.W.K.: Consultant for Medtronic, Fiagon, NeurEnt, GSK; Royalties from Medtronic. A.U.L.: Consultant for Aerin Medical (Sunnyvale, CA), Lyra Therapeutics (Watertown, MA), and Stryker (Kalamazoo, MI); Advisory board for ENTvantage (Austin, TX); Participated in advisory board meetings for Sanofi (Paris, France) and Novartis (Basel, Switzerland). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Publisher Copyright: {\textcopyright} 2020 ARS-AAOA, LLC",
year = "2020",
month = sep,
day = "1",
doi = "10.1002/alr.22633",
language = "English (US)",
volume = "10",
pages = "1037--1042",
journal = "International Forum of Allergy and Rhinology",
issn = "2042-6976",
publisher = "Wiley-Blackwell",
number = "9",
}